Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Immune Protocol

Magainin-2Complete Dosing & Administration Guide

Amphipathic 23-amino-acid antimicrobial peptide from Xenopus laevis skin — the founding member of the magainin family discovered by Michael Zasloff at NIH in 1987, operating through the toroidal pore membrane disruption model with broad-spectrum activity against Gram-positive and Gram-negative bacteria, whose synthetic derivative Pexiganan (MSI-78) advanced to Phase III clinical trials for diabetic foot ulcers

Dose Range

1-5mg

Frequency

Multiple times daily

Route

Topical application (primary clinical route)

Cycle Length

4-6 weeks

Dosing

How much
do I take?

Starting Dose

0.5-1% topical cream or 1-2 mg in research solution

Frequency

Once daily

Duration

3-5 days initial evaluation

Begin with low-concentration topical formulation for initial tolerability assessment. Pexiganan was studied at 1% and 2% cream concentrations in clinical trials. Apply thin layer to clean wound bed or infection site. In vitro research typically uses MIC-range concentrations (1-40 µg/mL for Pexiganan). Monitor for local irritation. This is an investigational compound — use under research supervision.

Standard Dose

1% topical cream (10 mg/g) or 2-3 mg in research solution

Frequency

Twice daily

Duration

7-14 days

Standard clinical concentration from Phase III trials. Pexiganan 1% cream applied twice daily to mildly infected diabetic foot ulcers for up to 14 days demonstrated efficacy comparable to oral ofloxacin. Ensure wound bed is clean and debrided before application. Cover with non-adherent wound dressing. Monitor wound healing progress and signs of infection resolution.

Advanced Dose

2% topical cream (20 mg/g) or 5 mg in research solution

Frequency

Twice daily

Duration

14-28 days

Higher concentration for recalcitrant wound infections or biofilm-involved infections. Pexiganan 2% cream was evaluated in clinical studies with maintained safety profile. Higher concentrations may enhance biofilm penetration and eradication. Extended treatment for chronic wounds. Monitor for increased local irritation. Combination with systemic antibiotics may be warranted for complex infections.

Timing

Best time to take

Apply Magainin-2 to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.

With food?

As a topical product, Magainin-2 is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.

If stacking

Magainin-2 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting Your Dose

Increase if

  • +You've tolerated the current dose for the recommended period without significant side effects
  • +Therapeutic goals haven't been met at the current dose level
  • +Your healthcare provider recommends dose escalation based on your response
  • +Lab work or clinical assessments support a higher dose

Decrease if

  • -Side effects are bothersome or impacting daily life despite management strategies
  • -You experience any signs of an adverse reaction
  • -Lab results indicate the need for dose reduction
  • -Your healthcare provider recommends a lower dose based on your response

Signs of right dose

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Dosing Calculator

Calculate Your Exact Dose

1
2
3
4

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The weight is on the label

Peptide vial
5mg

Select Weight

mg

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Administration

How do I
use it?

Reconstitution

What you need

  • Magainin-2 in its prescribed form
  • Clean, dry storage container
  • Measuring device if applicable (oral syringe, measuring cup)
  • Calendar or reminder app for dosing schedule

Example

Magainin-2 comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.

Use Magainin-2 exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.

Injection

Route

Magainin-2 is administered Topical application (primary clinical route)—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

Technique

  • 1.Follow the specific administration instructions for your Magainin-2 formulation
  • 2.Take or apply as directed by your healthcare provider
  • 3.Store properly between uses according to package instructions

Storage

Before reconstitution

Store Magainin-2 in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Magainin-2 should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Sample Daily Schedule

As prescribed (twice daily)

As prescribed by your healthcare provider injection

Site: Topical application (primary clinical route)—rotate sites if applicable

Maintain a consistent schedule for optimal results with Magainin-2. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is it
safe?

Safety Profile

Magainin-2 demonstrates favorable safety in topical antimicrobial wound care studies with minimal systemic absorption through intact skin. Local tissue irritation minimal at therapeutic concentrations (0.1-1% w/w); hemolytic activity negligible at concentrations <10 μM. No serious adverse events in Phase II wound healing trials. Peptide stability dependent on formulation pH; activity preserved at physiologic pH. Resistance development slower than traditional antibiotics.

Antimicrobial mechanism confirmed through electron microscopy demonstrating membrane pore formation in Gram-negative bacteria. MIC values of 2-10 μM for Pseudomonas aeruginosa and Staphylococcus aureus documented via broth microdilution assays. Wound healing studies using histopathology show accelerated re-epithelialization with faster collagen deposition. Safety dermatology testing confirms non-irritant status per OECD 404 at concentrations up to 2%.

Common Side Effects

Experienced by some users

Application site burning/stinging

Mild burning or stinging sensation at the topical application site, lasting 5-15 minutes after application. Reported in 5-10% of patients in Phase III trials.

Management: Self-limiting and resolves quickly. Cool compresses if needed. Does not require discontinuation of treatment.

Local erythema

Mild redness and warmth surrounding the application site, indicating local immune activation and vasodilation.

Management: Normal inflammatory response — often indicates active immune engagement with the infection. Monitor for progression. Resolves as treatment continues.

Mild pruritus

Itching at wound margins, more common during the healing phase as epithelial migration and nerve regeneration occur.

Management: Avoid scratching to prevent wound disruption. Cool compresses. Antihistamine cream at wound margins (not on wound bed) if needed.

Increased wound exudate

Transient increase in wound drainage in the first 24-48 hours as bacteria are killed and cellular debris is released.

Management: Change dressings more frequently. Normal response to bacterial killing. Should decrease by day 3-4 of treatment.

Less Common

  • Contact sensitization

These typically resolve with continued use or dose adjustment.

Stop and Seek Help If

  • ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • ×Your healthcare provider recommends discontinuation based on your clinical response
  • ×Development of any new medical condition that may be contraindicated with Magainin-2
  • ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • ×Abnormal lab results or clinical markers that suggest adverse effects

Magainin-2 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Interactions

With other peptides

  • May be used together under medical guidance.
  • May be used together under medical guidance.
  • May be used together under medical guidance.

With medications

  • !High concentrations of divalent cations (Ca²⁺, Mg²⁺) in wound care products — can reduce electrostatic binding of cationic magainin to bacterial membranes - Use with caution—discuss with your healthcare provider.
  • !Anionic wound dressings or polyanion-containing products (alginate, hyaluronic acid at high concentrations) — may sequester cationic magainin peptides - Use with caution—discuss with your healthcare provider.
  • !Topical corticosteroids at the same site — may impair the local immune activation that magainin promotes - Use with caution—discuss with your healthcare provider.

With supplements

  • Multivitamins - Generally safe to take alongside Magainin-2. Space doses apart if taking oral formulations to ensure optimal absorption.
  • Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Want the Full Picture?

View the complete Magainin-2 research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.

View Full Magainin-2 Profile

Medical Disclaimer

Magainin-2 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: 2/8/2026